Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2010-08-27 Investor Presentation
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Investor Presentation 2010
Investor Presentation Classification · 90% confidence The document text is a press release detailing a seminar held by Karo Bio regarding the development route for their drug eprotirome, featuring presentations from external professors and internal management. It discusses clinical trial plans (Phase III program), medical rationale, and market need for treating dyslipidemia in HeFH patients. This content is characteristic of an announcement providing updates on strategy, clinical progress, and expert opinions, often released to the public and investors. It is not a formal regulatory filing like a 10-K, a formal earnings release (ER), or a transcript of a call (CT). It most closely aligns with an Investor Presentation (IP) or a general update, but since it is structured as a news release summarizing a specific event (a seminar) focused on clinical/strategic direction, and given the options, it functions as a detailed update for investors. However, the content is a summary of a seminar, not a formal presentation deck itself. Since it is a detailed narrative update about strategy and clinical development, it fits best under the general category of Investor Presentation (IP) or potentially a Management Report (MDA) if it were more focused on financial performance explanation. Given the focus on clinical strategy and expert endorsement, IP is a strong fit, but since it's a press release *about* a seminar, and not the presentation slides themselves, it could also be considered a Regulatory Filing (RNS) if no better fit exists. Comparing IP (detailed presentation for investors) vs MDA (management's detailed explanation of results/trends), this is more about future strategy and clinical data presentation. Since it's a press release summarizing expert opinions and clinical plans, and not a formal presentation deck, the most appropriate classification among the specific options is often the one covering detailed strategic updates. Given the high level of detail on the clinical program and expert commentary, it leans towards Investor Presentation (IP) content being disseminated via a press release format. If it were purely a summary of results, ER or MDA would apply. Since it's a strategic update, IP is chosen, though RNS is a possibility if IP is reserved strictly for slide decks.
2010-08-27 English
Report Publication Announcement 2010
Report Publication Announcement Classification · 95% confidence The document is dated August 27, 2010, and discusses a well-attended seminar held by Karo Bio regarding their drug candidate eprotirome for treating HeFH. It details presentations by external experts (Professors Nissen and Kastelein) and Karo Bio's Chief Medical Officer (Jens Kristensen) about the clinical trial strategy (Phase III program) and the medical need. The text concludes by stating that presentations from the seminar will be available on the company website starting the next day. This structure—a summary of an event where information was presented, followed by a note that the presentation materials will be published separately—strongly indicates this document is an announcement about the event itself, rather than the full presentation or a formal regulatory report like an ER or IR. Since it announces the publication of materials related to a corporate event/strategy discussion, it fits best as an Investor Presentation (IP) announcement or, more generally, a Report Publication Announcement (RPA) if the focus is on the materials being made available. Given the content is a summary of a strategy seminar aimed at investors/experts, and it explicitly states where the presentations will be found, RPA is the most accurate classification for this announcement type, although IP is closely related to the content discussed. However, the 'MENU VS MEAL' rule suggests that if the actual presentation isn't here, but an announcement about its availability is, RPA is preferred over IP. Since the document is a press release summarizing a seminar and pointing to where the actual presentations will be posted, RPA is the best fit.
2010-08-27 Swedish
Regulatory Filings 2010
Regulatory Filings Classification · 96% confidence The document is a press release from Karo Bio, dated August 26, 2010, announcing the planned Phase III clinical program for their drug eprotirome for treating HeFH. It details the study design, primary endpoints, timeline for regulatory submission (EMA end of 2013/2014), and includes quotes from management and principal investigators. This content is characteristic of an initial announcement of significant clinical development plans and results, which aligns best with an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) or Investor Presentation (IP) if it were a slide deck. However, since it is a detailed announcement of clinical trial plans and strategy updates, and not a formal financial report (10-K, IR, MRQ) or a transcript (CT), it functions as a key piece of investor information. Given the focus on development plans and the fact that it is a press release announcing future steps and providing context on the drug and disease, it is most closely related to an Investor Presentation (IP) in terms of content depth, or a general Regulatory Filing (RNS) if it doesn't fit the specific financial/governance categories. Since it is a detailed announcement of clinical strategy and future milestones, 'Investor Presentation' (IP) is a strong fit for the informational content, although it is structured as a press release. Given the options, and the lack of a specific 'Clinical Update' code, 'IP' captures the forward-looking, strategic nature of the announcement better than the generic 'RNS'. The document is not short enough to be an RPA, nor is it a formal financial report.
2010-08-26 Swedish
Investor Presentation 2010
Investor Presentation Classification · 92% confidence The document is a press release from Karo Bio AB announcing the design of their Phase III clinical trials for the drug eprotirome. It details the study plan, endpoints, patient numbers, and timelines for regulatory submission (EMA in late 2013/2014). This content is characteristic of an initial announcement regarding clinical development progress, often released to the public and investors via a press release format. It is not a comprehensive Annual Report (10-K), a formal Audit Report (AR), a transcript (CT), or a formal regulatory filing like a proxy statement. Since it is an announcement detailing significant business/development news, it fits best under the general category of Investor Presentation (IP) if it were a slide deck, or more broadly, a press release announcing key operational/development milestones. Given the options, this is a detailed announcement of clinical development plans, which often accompanies or precedes an Investor Presentation, but the text itself functions as a detailed update. However, looking closely at the definitions, it is not a formal financial report (10-K, IR, ER, MRQ). It is a detailed update on a specific development program. Since it is a detailed presentation of development plans and scientific insights (including quotes from external experts), 'Investor Presentation' (IP) is the most fitting category for substantive, non-financial, forward-looking operational updates, even if delivered via a press release format. It is too detailed for a simple Earnings Release (ER) or a general Regulatory Filing (RNS).
2010-08-26 English
Investor Presentation 2010
Investor Presentation Classification · 92% confidence The document is a press release dated August 11, 2010, announcing that Karo Bio will present the development plan for its Phase III study of eprotirome for HeFH treatment during a seminar on August 26, 2010. It details the speakers (CMO, Professor Nissen, Professor Kastelein) and the topics to be covered, including regulatory landscape and clinical study insights. This is not a full financial report (10-K or IR), an earnings release (ER), or a formal regulatory filing like a DVA or DIV. It is an announcement about an upcoming investor/scientific event where strategic and development plans will be discussed in detail, which aligns best with an Investor Presentation (IP) or a general announcement about an upcoming event. Since the content is primarily focused on presenting future strategy and clinical plans to investors/stakeholders, 'Investor Presentation' (IP) is a strong candidate, although the document itself is an announcement *of* the presentation. Given the detailed nature of the announcement and the focus on future strategy and clinical development, it is more specific than a general Regulatory Filing (RNS). However, since the document is an announcement *about* a future presentation/seminar, and not the presentation material itself, it functions as a Report Publication Announcement (RPA) or a general announcement. Since the content is highly specific to future investor/scientific communication, and not just a generic 'report is coming' notice, I will lean towards the closest fit for strategic communication. If the seminar itself were attached, IP would be correct. As it is an announcement of the seminar, it is closest to a general announcement or a report publication announcement. Given the context of presenting development plans, it is a strategic communication. I will classify it as an Investor Presentation (IP) because the core purpose is to communicate strategic and development updates to the investment community, even if it's an announcement *for* the event, as it contains substantial strategic context. If 'RPA' was chosen, it would be because it announces the event, but 'IP' captures the substance better than a generic 'RPA' or 'RNS'. Given the length and detail, it's more than just a brief notice, suggesting the content is substantial, even if it's an invitation/summary for a future event. I will select IP based on the subject matter being investor-focused strategic updates.
2010-08-11 Swedish
Report Publication Announcement 2010
Report Publication Announcement Classification · 95% confidence The document is a press release dated August 11, 2010, announcing that Karo Bio will present its clinical Phase III development plan for eprotirome on August 26, 2010. It details the speakers (CMO, external professors) and the content of the upcoming seminar. Crucially, the text states: 'In our latest interim report we announced our plans to communicate further on the development of eprotirome in form of a seminar.' This indicates the document itself is an announcement about a future event/presentation, not the presentation material itself, nor a formal regulatory filing like a 10-K or an Earnings Release (ER). Since it is an announcement regarding the publication/presentation of future strategic and clinical information, it fits best under Report Publication Announcement (RPA) or potentially a general Regulatory Filing (RNS) if RPA is too specific. Given that it is announcing the details of a planned presentation/seminar, RPA is the most appropriate fit, as it signals the upcoming release of detailed information.
2010-08-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.